Posts by John

AbCellera’s ABCL635 shows promise in Phase 2 trials, significantly reducing hot flash frequency and severity with a favorable safety profile.

New Phase 2 data confirms ABCL635 significantly reduces hot flash severity and frequency, offering a promising non-hormonal breakthrough for patient care.

Veru reports Q3 fiscal results and provides a critical update on the Phase 2b PLATEAU trial for enobosarm, a candidate targeting muscle-wasting conditions.

Explore the rapid rise of radiopharmaceuticals, the clinical promise of targeted cancer therapy, and the critical safety hurdles facing this field.

China is tightening its clinical trial oversight. Explore how this shift affects global drug development and the U.S. quest for improved research speed.

ICON and Anthropic are partnering to integrate generative AI into clinical trials. Discover how this shift will impact drug development and site operations.

A new AI audit framework fills the FDA's regulatory gap for mental health tools, focusing on clinical safety, diagnostic accuracy, and algorithmic fairness.

Akeso has dosed the first patient in a Phase II trial testing the combination of AK146D1 and ivonescimab to treat advanced breast cancer. Learn more.

A Mangaluru police official faces criminal charges for medical reimbursement fraud. Discover the impact on healthcare oversight and financial integrity.

Psychedelic therapy is nearing a clinical breakthrough. Explore the latest on MDMA and psilocybin research, regulatory shifts, and the future of psychiatry.